ESR1 and neoplasm: Decisions about adjuvant treatment have traditionally been based upon prognostic factors such as age, tumor size, histological grade, proliferation, lymph node involvement, HER2 status, estrogen receptor (ER), progesterone receptor (PgR), and gene expression assays like Oncotype DX [1].